Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 3/20 | 0.67 |
| ▸ | TCF4 | P15884 | 2/20 | 0.67 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.67 |
| ▸ | TCF7 | P36402 | 2/20 | 0.56 |
| ▸ | CLPP | Q16740 | 2/20 | 0.56 |
| ▸ | BCL9 | O00512 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 16/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15962638 | 1.00 | CTNNB1 (0.67) | CTNNB1TCF4CREBBPTCF7CLPP | |
| SCHEMBL29506801 | 1.00 | CTNNB1 (0.67) | CTNNB1TCF4CREBBPTCF7CLPP | |
| SCHEMBL1591177 | 1.00 | CTNNB1 (0.67) | CTNNB1TCF4CREBBPTCF7CLPP | |
| SCHEMBL15309304 | 0.97 | CTNNB1 (0.63) | CTNNB1TCF4CREBBPTCF7CLPP | |
| SCHEMBL15309547 | 0.95 | CTNNB1 (0.61) | CTNNB1TCF4CREBBPTCF7CLPP | |
| SCHEMBL15309477 | 0.94 | CTNNB1 (0.64) | CTNNB1TCF4CREBBPTCF7CLPP | |
| SCHEMBL15309631 | 0.93 | CTNNB1 (0.59) | CTNNB1TCF4CREBBPTCF7CLPP | |
| SCHEMBL29506800 | 0.93 | CTNNB1 (0.65) | CTNNB1TCF4CREBBPTCF7CLPP | |
| SCHEMBL1591567 | 0.93 | CTNNB1 (0.65) | CTNNB1TCF4CREBBPTCF7CLPP | |
| SCHEMBL16966310 | 0.92 | CTNNB1 (0.65) | CTNNB1TCF4CREBBPTCF7CLPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353119-B2 | Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives | JW PHARMACEUTICAL CORPORATION (KR) | 2016-05-31 | — | — | US | disclosed |
| US-9353119-B2 | Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives | JW PHARMACEUTICAL CORPORATION (KR) | 2016-05-31 | — | — | US | disclosed |
| US-20140235581-A1 | COMPOSITION FOR PREVENTING AND TREATING NON-SMALL CELL LUNG CANCER, CONTAINING PYRAZINO-TRIAZINE DERIVATIVES | JW PHARMACEUTICAL CORPORATION (KR) | 2014-08-21 | — | — | US | disclosed |
| US-20140235581-A1 | COMPOSITION FOR PREVENTING AND TREATING NON-SMALL CELL LUNG CANCER, CONTAINING PYRAZINO-TRIAZINE DERIVATIVES | JW PHARMACEUTICAL CORPORATION (KR) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235581-A1 | COMPOSITION FOR PREVENTING AND TREATING NON-SMALL CELL LUNG CANCER, CONTAINING PYRAZINO-TRIAZINE DERIVATIVES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, HDAC5 | CTNNB1 893/4885TCF4 1126/4885CREBBP 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.